-
Essentialis Inc. (San Diego, Calif.) reported data from a Phase IIb trial in 44 non-diabetics with fasting triglyceride levels of at least 500 mg/dL evaluating diazoxide choline controlled release (DCCR) in combination …
Published on 2/29/2012
-
NIH launched the Genetic Testing Registry, a free searchable database of information on a genetic test's purpose, methodology, validity and evidence of usefulness. The registry will use data voluntarily submitted by …
Published on 2/29/2012
-
AspenBio Pharma Inc. (NASDAQ:APPY) said a cassette-based version of AppyScore had a negative predictive value of 97%, sensitivity of 96% and specificity of 43% for diagnosing appendicitis in a U.S. pilot trial in 503 …
Published on 2/28/2012
-
Cleveland-based University Hospitals launched the Harrington Project for Discovery & Development to advance research projects to commercialization. The initiative establishes the UH Harrington Discovery Institute to …
Published on 2/28/2012
-
BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) gained $0.10 (14%) to $0.81 on Monday after reporting data from a Phase Ib trial of GVAX Pancreas cancer vaccine plus ipilimumab to treat previously treated, locally advanced …
Published on 2/27/2012
-
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported interim data from 46 treatment-naive patients with chronic HCV genotype 1a or 1b infection who received twice-daily 400 mg VX-222 plus Incivek telaprevir and ribavirin …
Published on 2/23/2012
-
GTx Inc. (NASDAQ:GTXI) fell $2.11 (36%) to $3.69 on Tuesday after FDA placed a clinical hold on Capesaris (GTx-758) following reports of an increased risk of venous thromboembolic events (VTE) in patients receiving the …
Published on 2/21/2012
-
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said vedolizumab met the co-primary endpoints in the Phase III GEMINI I trial to treat moderate to severe ulcerative colitis. The humanized mAb against integrin alpha(4)beta(7…
Published on 2/21/2012
-
UCB Group (Euronext:UCB) said Cimzia certolizumab significantly improved signs and symptoms of psoriatic arthritis from baseline to week 12 vs. placebo in the Phase III RAPID-PsA trial in 409 patients with adult-onset …
Published on 2/16/2012
-
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.44 (12%) to $4.11 on Wednesday after reporting "favorable" preclinical data for HCV product BCX5191. BioCryst said in vitro and in vivo studies showed that submolar …
Published on 2/15/2012
-
AiCuris GmbH & Co. KG (Wuppertal, Germany) said once-daily 240 mg oral letermovir met the co-primary endpoints in a Phase II trial to prevent cytomegalovirus (CMV) infection in human blood precursor cell (HBPC) …
Published on 2/14/2012
-
Karo Bio AB (SSE:KARO) fell SEK0.82 (68%) to SEK0.38 on Tuesday after discontinuing development of eprotirome based on data from a 12-month toxicity study in dogs. Karo Bio said the thyroid hormone receptor agonist, …
Published on 2/14/2012
-
BG Medicine Inc. (NASDAQ:BGMD) said that testing with its CardioScore diagnostic at baseline significantly improved the identification of subjects at high risk for near-term major cardiovascular events over conventional…
Published on 2/13/2012
-
Verinata Health Inc. (Redwood City, Calif.) reported top-line data from the prospective MELISSA validation trial of its verifi prenatal test to identify multiple fetal chromosomal abnormalities from maternal blood. In …
Published on 2/13/2012
-
The Moffitt Cancer Center, Sanford-Burnham Medical Research Institute and Florida Hospital partnered to launch the Personalized Medicine Partnership of Florida to discover and develop therapies for cancer and metabolic …
Published on 2/8/2012
-
Forest Laboratories Inc. (NYSE:FRX) and partner Gedeon Richter Ltd. (Budapest:RICHTER) said cariprazine met the primary endpoint in a Phase III trial to treat acute mania associated with bipolar I disorder. The partial …
Published on 2/8/2012
-
Merck & Co. Inc. (NYSE:MRK) said vorapaxar met the composite primary endpoint in the Phase III TRA-2P trial to treat and prevent arterial thrombosis associated with atherosclerosis. The product plus standard of care …
Published on 2/7/2012
-
ChemoCentryx Inc. (Mountain View, Calif.) said it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will discontinue development of CCX832 and its two backup compounds. ChemoCentryx said the decision was based on …
Published on 2/6/2012
-
Chimerix Inc. (Durham, N.C.) said twice-weekly 100 mg CMX001 met the primary endpoint in a Phase II trial (Study 201) to treat and prevent cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) …
Published on 2/6/2012
-
Orexigen Therapeutics Inc. (NASDAQ:OREX) said it reached agreement with FDA on an SPA for the cardiovascular outcomes trial of obesity product Contrave that the agency requested in a complete response letter last year. …
Published on 2/6/2012
-
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) said partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) suspended enrollment in all trials of GSK2251052 following a "microbiological finding in a small number of patients" in a …
Published on 2/6/2012
-
Genfit S.A. (Euronext:ALGFT) gained EUR 1.57 (84%) to EUR 3.45 on Friday after GFT505 met the co-primary endpoints of improving insulin sensitivity in the liver and peripheral tissues in the Phase II GFT505-210-6 trial …
Published on 2/3/2012
-
AB Science S.A. (Euronext:AB) jumped EUR 4.42 (72%) to EUR 10.60 on Thursday after releasing data late Wednesday from a Phase II trial of masitinib to treat gastrointestinal stromal tumors (GIST). Second-line treatment …
Published on 2/2/2012
-
Astellas Pharma Inc. (Tokyo:4503) said oral JAK inhibitor ASP015K met the primary endpoint of significantly improving Psoriasis Area and Severity Index (PASI) score from baseline to day 42 vs. placebo in a Phase IIa …
Published on 2/2/2012
-
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) said a greater proportion of patients receiving OGX-427 plus prednisone were progression free at 12 weeks, the primary endpoint, vs. prednisone alone in a Phase II trial to …
Published on 2/2/2012